STOCK TITAN

BioHarvest Sciences Announces Closing of USD $4,329,982 in First Tranche of Private Placement and Conversion of Debt Notes

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
private placement
Rhea-AI Summary

BioHarvest Sciences (CSE: BHSC, OTCQB: CNVCD, FSE: 8MV) has successfully closed the first tranche of its private placement, raising USD $4,329,982.62. The company issued 603,904 share units at USD $7.17 per unit. Each unit includes one common share, one-quarter of a USD $7.68 warrant expiring in 6 months, and one-quarter of a USD $11.52 warrant expiring in 18 months. These funds will support the CDMO business unit, expand manufacturing capabilities, and cover general corporate expenses.

Additionally, BioHarvest announced the conversion of CAD $288,933.09 in convertible debt notes from previous financing rounds into 33,697 common shares. The company also issued 20,242 'Early Exercise' warrants at USD $7.70, expiring on December 22, 2025. Over 93% of the company's convertible notes have now been exercised.

Positive
  • BioHarvest raised USD $4,329,982.62 in the first tranche of its private placement.
  • Funds will support the CDMO business unit and expand manufacturing capabilities.
  • Over 93% of convertible notes have been exercised, indicating strong investor confidence.
Negative
  • The issued securities are subject to hold periods, potentially limiting short-term liquidity for investors.

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 28, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) ("BioHarvest" or the "Company") has closed the first tranche of its private placement announced on June 21, 2024. The Company issued 603,904 share units at USD $7.17 per unit raising a total of USD $4,329,982.62 (approx. CAD $5,926,000). Each unit includes one common share, one-quarter of a USD $7.68 warrant expiring in 6 months, and one-quarter of a USD $11.52 warrant expiring in 18 months.

Consequently, the Company issued 150,978 warrants to purchase one common share at USD $7.68 within six months, and 150,978 warrants to purchase one common share at USD $11.52 within eighteen months.

The securities issued under the private placement will be subject to a hold period expiring four months and one day from the date of issuance, pursuant to applicable Canadian securities laws. US placees will also be subject to US hold periods and their shares appropriately legended.

The funds raised will support the Company's Contract Development and Manufacturing Organization (CDMO) business unit, expand manufacturing capabilities at the newly acquired 80,000 square foot campus, and be used for general corporate purposes.

Additionally, the Company announces the early conversion of convertible debt notes from financing rounds completed in October 2022 and December 2023.

BioHarvest reports that CAD $288,933.09 of principal loans plus accrued interest has been converted into 33,697 common shares. In line with the December 2023 convertible loans, the Company has issued 20,242 "Early Exercise" warrants at USD $7.70 expiring on December 22, 2025. Each warrant allows the holder to purchase one common share at USD $7.70.

With this conversion, over 93% of the Company's convertible notes have now been exercised.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/214915

FAQ

What is the amount BioHarvest Sciences raised in the first tranche of its private placement?

BioHarvest Sciences raised USD $4,329,982.62 in the first tranche of its private placement.

What is the stock symbol for BioHarvest Sciences?

The stock symbol for BioHarvest Sciences is CNVCD.

What are the terms of the warrants issued by BioHarvest Sciences in the private placement?

BioHarvest Sciences issued warrants to purchase one common share at USD $7.68 within six months, and at USD $11.52 within eighteen months.

When do the securities issued by BioHarvest Sciences in the private placement become tradeable?

The securities will be tradeable after a hold period of four months and one day from the date of issuance.

What percentage of BioHarvest Sciences' convertible notes have been exercised?

Over 93% of BioHarvest Sciences' convertible notes have been exercised.

What will BioHarvest Sciences use the funds raised from the private placement for?

BioHarvest Sciences will use the funds to support its CDMO business unit, expand manufacturing capabilities, and for general corporate purposes.

BIOHARVEST SCIENCES NEW

OTC:CNVCD

CNVCD Rankings

CNVCD Latest News

CNVCD Stock Data

103.71M
United States of America